Johnson & Johnson’s Rybrevant-Lazcluze Combination Shows Superior Survival Trend Over AstraZeneca’s Tagrisso in EGFR-Mutated Lung Cancer

Superior Survival Trend:
The combination of Rybrevant and Lazcluze demonstrated a favorable overall survival trend compared to osimertinib (Tagrisso) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).

Three-Year Survival Rates:
At three years (median follow-up of 31.1 months), 61% of patients receiving Rybrevant plus Lazcluze were alive, compared to 53% of those treated with osimertinib.

Central Nervous System Disease Control:
The Rybrevant-Lazcluze combination showed a trend toward improved central nervous system disease control compared to osimertinib at three years, with intracranial PFS being double for Rybrevant plus Lazcluze (38% vs 18%).

Treatment Duration and Subsequent Therapy:
More patients remained on treatment at three years with the Rybrevant combination compared to osimertinib, and more patients receiving Rybrevant and Lazcluze had not started a subsequent therapy versus osimertinib.

Approval:
The U.S. Food and Drug Administration (FDA) approved Rybrevant plus Lazcluze for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

MARIPOSA Study:
The Phase 3 MARIPOSA study demonstrated that first-line treatment with Rybrevant combined with Lazcluze provided consistent benefits across long-term outcomes compared to osimertinib monotherapy.